Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

Journal: The lancet. Gastroenterology & hepatology
PMID: 28404108

Abstract

BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial data for treatment remain limited. We assessed the combination of two direct-acting antivirals, ombitasvir (NS5A inhibitor) and paritaprevir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV genotype 4 infection and compensated cirrhosis.

Authors

  • Tarik Asselah
    Service d'Hépatologie, AP-HP Hôpital Beaujon, Clichy, Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Paris, France.
  • Christophe Hézode
    Hôpital Henri Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France.
  • Roula B Qaqish
    AbbVie Incorporated, North Chicago, IL, USA.
  • Magdy ElKhashab
    Toronto Liver Centre, University of Toronto, Toronto, ON, Canada.
  • Tarek Hassanein
    Southern California Liver Centers and Southern California Research Center, Coronado, CA, USA.
  • George Papatheodoridis
    Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • Jordan J Feld
    Toronto Centre for Liver Disease, University of Toronto, Toronto, ON, Canada.
  • Christophe Moreno
    CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Stefan Zeuzem
    JW Goethe University, Frankfurt, Germany.
  • Peter Ferenci
    Medical University Vienna, Vienna, Austria.
  • Yao Yu
    AbbVie Inc, North Chicago, IL, USA.
  • Rebecca Redman
    AbbVie Incorporated, North Chicago, IL, USA.
  • Tami Pilot-Matias
    AbbVie Inc, North Chicago, IL, USA.
  • Niloufar Mobashery
    AbbVie Incorporated, North Chicago, IL, USA.

Keywords

External Resources

Popular Topics
Recent Journals